You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 1
  • 93 Prognostic value of PTEN, BCL2 and PIK3CA expression in high-grade serous ovarian cancer treated with first line platinum derivative based chemotherapy

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
06. Ovarian cancer
93 Prognostic value of PTEN, BCL2 and PIK3CA expression in high-grade serous ovarian cancer treated with first line platinum derivative based chemotherapy
  1. Bartosz Szymanowski1,
  2. Michal Bienkowski2,
  3. Renata Duchnowska1,
  4. Rafal Peksa2 and
  5. Szczepan Cierniak3
  1. 1Military Institute of Medicine – National Research Institute, Oncology Department, Warsaw, Poland
  2. 2Medical University of Gdansk, Department of Pathomorphology, Gdansk, Poland
  3. 3Military Institute of Medicine – National Research Institute, Department of Pathomorphology, Warsaw, Poland

Abstract

Introduction/Background PTEN (phosphatase and tensin homolog deleted on chromosome ten), BCL2 (B-cell lymphoma-2) and PIK3CA (phosphatidylinositol 3 kinase) are connected with pathways potentially associated with resistance to chemotherapy.

Methodology The study group included 64 Caucasian women with serous high-grade ovarian cancer (HGSOC) stage III-IV TNM/FIGO classification, treated 1st line platinum derivative based chemotherapy between 2004–2014. The analysis of clinical data was carried out based on data from medical records. PTEN, BCL2 and PIK3CA expression was assessed by immunohistochemistry using respectively: DAKO monoclonal mouse, clone 6H2.1, DAKO monoclonal mouse, clone 124 and Cell signaling Rabbit monoclonal, clone C73F8 antibodies in tissues from paraffin-embedded blocks. Progression free survival (PFS) was analyzed as the time from the start of chemotherapy to progression. Overall survival (OS) was defined as the time from diagnosis to the patient’s death, regardless of cause. Statistical analysis was performed using the 3.4.3 version of R statistical environment.

Results The median follow-up was 1023 days (range 157 to 3420 days). The median PFS was 14.0 (95%CI: 11.9–18.0) months. Median OS was not reached. The average patients age was 62 years (range 37–83). Platinum-sensitivity, partial platinum-sensitivity, platinum resistance and platinum-insensitivity were found in 23 (37.1%), 17 (27.4%), 21 (33.9%) and 1 (1.6%) patients, respectively. Any expression of PTEN, BCL2 and PIK3CA were noted in 53, 31 and 53 patients respectively. In multivariate analysis PFS was associated with the extent of surgery: cytoreduction secondary vs. primary (WR = 1.94; p = 0.03), suboptimal vs. optimal (WR = 2.16; p = 0.01), body mass index (WR = 0.44; p = 0.05) however there was no association between PFS and expression of PTEN, BCL2 and PIK3CA.

Conclusion PTEN, BCL2 and PIK3CA expression were not prognostic and predictive biomarkers in HGSOC treated with platinum derivatives regiments.

Disclosures No disclosures.

https://doi.org/10.1136/ijgc-2024-ESGO.566

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.